- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DISHMAN PHARMA - DIVIS LABORATORIES
DISHMAN PHARMA vs DIVIS LABORATORIES - Comparison Results
DISHMAN PHARMA 
Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
DIVIS LABORATORIES
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Current Valuations
| DISHMAN PHARMA | DIVIS LABORATORIES | DISHMAN PHARMA/ DIVIS LABORATORIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | 32.2 | 77.9% | View Chart |
| P/BV | x | 3.3 | 5.8 | 58.1% | View Chart |
| Dividend Yield | % | 0.7 | 0.9 | 77.3% |
Financials
 DISHMAN PHARMA  DIVIS LABORATORIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
DIVIS LABORATORIES Mar-17 |
DISHMAN PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 1,222 | 30.6% | |
| Low | Rs | 129 | 784 | 16.4% | |
| Sales per share (Unadj.) | Rs | 197.8 | 153.1 | 129.2% | |
| Earnings per share (Unadj.) | Rs | 21.2 | 39.9 | 53.1% | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 44.6 | 77.9% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 10.00 | 20.0% | |
| Dividend yield (eoy) | % | 0.8 | 1.0 | 79.7% | |
| Book value per share (Unadj.) | Rs | 179.9 | 201.8 | 89.1% | |
| Shares outstanding (eoy) | m | 80.69 | 265.47 | 30.4% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 6.6 | 19.4% | |
| Avg P/E ratio | x | 11.9 | 25.1 | 47.3% | |
| P/CF ratio (eoy) | x | 7.2 | 22.5 | 32.2% | |
| Price / Book Value ratio | x | 1.4 | 5.0 | 28.1% | |
| Dividend payout | % | 9.4 | 25.0 | 37.7% | |
| Avg Mkt Cap | Rs m | 20,306 | 266,266 | 7.6% | |
| No. of employees | `000 | 0.8 | 9.7 | 8.5% | |
| Total wages/salary | Rs m | 5,355 | 4,687 | 114.2% | |
| Avg. sales/employee | Rs Th | 19,252.7 | 4,175.0 | 461.1% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 481.5 | 1,341.5% | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 1,089.3 | 189.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 40,643 | 39.3% | |
| Other income | Rs m | 265 | 749 | 35.4% | |
| Total revenues | Rs m | 16,226 | 41,392 | 39.2% | |
| Gross profit | Rs m | 4,103 | 14,460 | 28.4% | |
| Depreciation | Rs m | 1,091 | 1,233 | 88.4% | |
| Interest | Rs m | 944 | 23 | 4,178.8% | |
| Profit before tax | Rs m | 2,334 | 13,953 | 16.7% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 624 | 3,349 | 18.6% | |
| Profit after tax | Rs m | 1,711 | 10,604 | 16.1% | |
| Gross profit margin | % | 25.7 | 35.6 | 72.3% | |
| Effective tax rate | % | 26.7 | 24.0 | 111.3% | |
| Net profit margin | % | 10.7 | 26.1 | 41.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 40,105 | 27.5% | |
| Current liabilities | Rs m | 9,517 | 6,595 | 144.3% | |
| Net working cap to sales | % | 9.4 | 82.5 | 11.4% | |
| Current ratio | x | 1.2 | 6.1 | 19.0% | |
| Inventory Days | Days | 110 | 119 | 93.2% | |
| Debtors Days | Days | 35 | 81 | 43.2% | |
| Net fixed assets | Rs m | 16,304 | 19,995 | 81.5% | |
| Share capital | Rs m | 161 | 531 | 30.4% | |
| "Free" reserves | Rs m | 12,907 | 53,043 | 24.3% | |
| Net worth | Rs m | 14,516 | 53,574 | 27.1% | |
| Long term debt | Rs m | 4,189 | 0 | - | |
| Total assets | Rs m | 29,805 | 61,585 | 48.4% | |
| Interest coverage | x | 3.5 | 618.4 | 0.6% | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.5 | 0.7 | 81.1% | |
| Return on assets | % | 8.9 | 17.3 | 51.6% | |
| Return on equity | % | 11.8 | 19.8 | 59.6% | |
| Return on capital | % | 17.5 | 26.1 | 67.2% | |
| Exports to sales | % | 24.8 | 0 | - | |
| Imports to sales | % | 3.7 | 25.2 | 14.8% | |
| Exports (fob) | Rs m | 3,956 | NA | - | |
| Imports (cif) | Rs m | 596 | 10,259 | 5.8% | |
| Fx inflow | Rs m | 4,952 | 35,384 | 14.0% | |
| Fx outflow | Rs m | 697 | 10,399 | 6.7% | |
| Net fx | Rs m | 4,255 | 24,985 | 17.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 11,493 | 24.2% | |
| From Investments | Rs m | -1,529 | -11,372 | 13.4% | |
| From Financial Activity | Rs m | -941 | -93 | 1,010.8% | |
| Net Cashflow | Rs m | 316 | 28 | 1,114.1% | |
Share Holding
| Indian Promoters | % | 61.4 | 52.0 | 118.1% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 3.7 | 11.8 | 31.4% | |
| FIIs | % | 12.7 | 19.0 | 66.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 22.1 | 17.2 | 128.5% | |
| Shareholders | 46,261 | 31,796 | 145.5% | ||
| Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: NATCO PHARMA PANACEA BIOTECH FDC LTD. TORRENT PHARMA PLETHICO PHARMA
Compare DISHMAN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Of Depreciating Rupee; IPO Buzz and Top Cues in Focus Today(Pre-Open)
Indian share markets ended lower yesterday with banking stocks and metal stocks leading the losses. At the closing bell, the BSE Sensex ended down by 188 points (0.5%).
Related Views on News
DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)
May 28, 2018 | Updated on May 28, 2018For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)
Aug 7, 2018Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA 5-YR ANALYSIS
COMPARE DISHMAN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.